(Q82351260)
Statements
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy (English)
Baete Luxembourg
Katharina Schneider
Katja Sittinger
Stefan W Toennes
Erhard Seifried
Edelgard Lindhoff-Last
Johannes Oldenburg